Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Despite heart failure with preserved ejection fraction (HFpEF) accounting for approximately half of all chronic heart failure (CHF) cases, and despite our improved understanding of the pathophysiology, pharmacological treatments with proven outcomes benefits in HFpEF have been elusive thus far. Indeed, clinical trials of agents with proven efficacy in reduced ejection fraction (HFrEF) patients have consistently fallen short in HFpEF studies. Drug treatment, therefore, focuses on the management of comorbidities, with first-line treatment typically consisting of RAAS inhibitors, beta blockers, and diuretics. Unlike in HFrEF, calcium channel blockers can be used in this subpopulation. This analysis provides insights into the U.S. prescribing patterns in this heterogeneous and highly prevalent subpopulation.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Already a Client? Log in to access this report.
Dwaipayan Chatterjee is an Analyst in the Cardiovascular, Metabolism Renal and Hematology disease team at Decision Resources Group. He holds a degree with specialization in Pharmaceutical Chemistry from Birla Institute of Technology & Science, Pilani, Rajasthan, India. Prior joining DRG, he worked as an Equity Analyst for the Healthcare sector with Market Realist working on competitive intelligence and analysis of pharmaceutical financial data. He also worked as a market research analyst for Mordor Intelligence with experience of market sizing, forecasting, and analyzing market dynamics.